Long biologic exclusivity provisions fit perfectly into the category of misguided intellectual property provisions pushed by U.S. negotiators in FTAs. Such a provision would not open markets or even promote innovation. Instead, it would tie the hands of U.S. policymakers for the benefit of one part of one industry, while reducing the overall benefits to the U.S. economy.